Clinical Trials
39
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (34 trials with phase data)• Click on a phase to view related trials
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
- Conditions
- Cognitive DeclineObstructive Sleep Apnea
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-06-22
- Target Recruit Count
- 200
- Registration Number
- NCT05988385
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸New York University, New York, New York, United States
🇺🇸Mount Sinai, New York, New York, United States
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
- Conditions
- Uveal Melanoma
- Interventions
- Radiation: stereotactic body radiotherapyDrug: Immunotherapy
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2022-12-06
- Target Recruit Count
- 40
- Registration Number
- NCT05077280
- Locations
- 🇺🇸
California Pacific Medical Center Research Institute, San Francisco, California, United States
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2022-12-06
- Target Recruit Count
- 41
- Registration Number
- NCT04633902
- Locations
- 🇺🇸
California Pacific Medical Center Research Institute, San Francisco, California, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
CBT-I or Zolpidem/Trazodone for Insomnia
- Conditions
- Chronic Insomnia
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 155
- Registration Number
- NCT04468776
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸University of Missouri, Columbia, Missouri, United States
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2021-10-22
- Target Recruit Count
- 41
- Registration Number
- NCT03925350
- Locations
- 🇺🇸
California Pacific Medical Center Research Institute, San Francisco, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next